We are delighted to announce Illumina Accelerator is accepting applications for its next global funding cycle in the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator is the world’s first business accelerator focused on creating an innovation ecosystem for the genomics industry.
News
We continue to feel the impact of COVID-19, on a personal, organisational and national level.
For those working in supply chain management, COVID-19 has been the latest in a recent series of disruptive global challenges, including volcanic eruptions, earthquakes and war. Such global challenges undoubtedly lead to supply chain shock.
Unlike some challenges which are contained within regions, states or continents, the pandemic has sent shockwaves across the entire globe. As a result, all international supply chains have felt the effects of COVID-19.
- Long-term partnership to facilitate cancer research through development of custom antibodies
- Agreement to enable global access to resulting reagents and potential diagnostics
Reading Scientific Services Ltd (RSSL) has received the MHRA-recognised Cogent Gold Standard approval for its Responsible Person (RP) training course. The announcement follows a rigorous 18-month process, during which RSSL successfully developed and mapped all of its course material against the Gold Standard requirements.
CAMBRIDGE, UK– 6 July 2020 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that it has raised $15m (£12m) in equity investment.
Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory sites into 500m2 of laboratory and co-located office space in The Biosphere, which forms part of the Newcastle Helix cluster.
Cambridge, UK, 22nd June 2020: TTP plc (TTP), a leading independent technology and product development company, today announced that it has entered into a technology advisory partnership with Cancer Research UK. TTP has been selected by Cancer Research UK to apply its technology design and development expertise and insight in the healthcare sector, to assess discoveries made by the charity’s academic researchers.
AMSBIO has launched a range of ready-to-use SARS-CoV-2 Spike protein coupled magnetic beads that combine convenience, minimum non-specific binding and developed operational protocols saving you time and hassle.